Drugs / NY-ESO-1ᶜ²⁵⁹T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01350401 | Jun 2011 → Feb 2016 | melanoma | Adaptimmune | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1ᶜ²⁵⁹T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01350401 ↗ |
| Modality | Cell therapy | “autologous genetically modified T cells” NCT01350401 ↗ |